In the past few years, a number of hematopoietic SCTs (HSCTs) have been performed in erythropoietic protoporphyria (EPP). A summary and interpretation of the collected experience may serve to formulate possible indications for HSCT in EPP.
Erythropoietic protoporphyria is an inherited disorder of heme synthesis caused by mutations in the ferrochelatase (FECH) gene. The consequential reduction of enzyme activity results in the accumulation of protoporphyrin, a hydrophobic and highly photoactive substance, which is excreted solely through the hepatobiliary route. For the majority of patients, EPP is a psychosocially disabling, but not life-threatening, disease with painful photosensitivity. Severe liver disease requiring life-saving liver transplantation (LT) occurs in a few percent of cases. HSCT has been discussed as a potential treatment, but has not been used until recently. Apart from a fear of inherent HSCT risks, there has been an uncertainty about whether EPP is a strictly erythropoietic porphyria. Possibly, there may be individual heterogeneity with significant hepatic contribution to the excess protoporphyrin in some individuals. 1 In addition, loss of photosensitivity has been described after LT. 2, 3 If there truly are dual target organs in EPP, erythroid ferrochelatase replacement by HSCT might not be sufficient to cure photosensitivity and prevent future liver disease.
The experience from HSCT in EPP is growing. The first case was reported in 2002. 4 A woman with adult onset of severe photosensitivity was diagnosed with myelodysplastic syndrome. HSCT was indicated when she later developed acute myelogenous leukemia. HSCT cured photosensitivity and she became a single FECH mutation carrier, the same as her donating brother. Inherited EPP is typically caused by a FECH mutation and on the other allele by an intron polymorphism. In this case, 4 the second mutation might have been caused by myelodysplastic syndrome. 5 If so, she was a heterozygous mutation carrier outside the marrow, and conclusions about the role of the liver may not be drawn. The case did, however, pave the way for subsequent cases.
Four other cases were subsequently treated by HSCT around the same time. An American boy was treated with HSCT after LT. 6 A 20-year-old man in France and a 6-year-old boy in Holland underwent sequential LT-HSCT to prevent recurrent liver disease. In England, a 57-year-old man received sequential LT-HSCT due to recurrent liver disease. In our own center, HSCT was performed without antecedent LT after medical reversal of protoporphyric liver failure in a 63-year-old man. 7 HSCT in an American patient after two LTs has also been briefly mentioned. 8 These cases may be used as a background when discussing the role for HSCT in EPP. In view of the benign nature of uncomplicated EPP, it is not reasonable to use HSCT in the treatment of photosensitivity. Even if reduced conditioning is used, HSCT risks are significant. The role for HSCT in EPP is therefore intimately connected to liver disease.
The majority of those who develop liver failure already have cirrhosis. 8 Recurrent graft disease after LT occurred in 65% of patients surviving 42 months in the American cohort, leading to retransplantation in a few. 8 In an older patient, it may be reasonable to wait, as recurrence before HSCT, to save the graft and to prolong life, is contemplated. The English case illustrates this scenario.
The likelihood of significant recurrence is probably high in the young LT recipient with a long anticipated life span. This justifies the rationale of pre-emptive HSCT as secondary prophylaxis. The American, 6 French and Dutch cases illustrate this strategy.
Cholestatic liver failure may strike before advanced liver fibrosis is present, but this seems to be uncommon. We have seen two such patients in our center. 7 These patients have clearly shown a propensity for potentially fatal EPP liver disease. If the failing liver function can be reversed, HSCT should be contemplated to avoid an eventual LT and possibly subsequent HSCT. Our case illustrates this strategy. 7 Ideally, patients with progressive liver disease are identified before advanced fibrosis that prevents HSCT is present. It is presently not possible to identify patients at risk for severe liver disease. Postulated prognostic risk factors 7, 9 are hampered by inconsistent evidence, but with vigilant surveillance programs, 9,10 progressive fibrosis might be possible to detect in time.
Different scenarios (Figure 1 ) thus offer possible indications for HSCT in EPP:
1. After reversal of liver failure in patients without advanced liver fibrosis; 2. After LT in older patients with recurrent graft disease; 3. After LT in young patients; 4. Patients with progressive liver disease.
At least four of these cases allow some conclusions to be drawn regarding HSCT effects. The American 6 and Dutch boys, as well as our case, 7 attained biochemical and clinical resolution. The English patient died from infectious complications within a few months but normalized porphyria biochemistry before then. The French case never achieved marrow engraftment.
Our case is in excellent condition 3 years after successful HSCT. The EPP genotype is not present in peripheral blood cells, but is still present in dermal fibroblasts. Porphyrin biochemistry is normal and photosensitivity is completely absent. The liver has not been histologically examined again, as liver function tests have remained normal.
These cases illustrate issues concerning indications, timing and patient selection. If the observation that the liver might contribute significantly in some patients is true, HSCT as monotherapy might not offer a cure from photosensitivity and future liver disease. If the index case with myelodysplastic syndrome is excluded for stated reasons, the experience answering the concern for significant liver contribution is limited to one case, 7 as this concern is eliminated when serial LT-HSCT is performed. HSCT does appear to cure the EPP phenotype, although additional cases are needed to alleviate the theoretical concerns regarding efficacy as monotherapy.
Ideally, HSCT is performed in the EPP patient prone to severe liver disease before a need for LT is present. Better prognostic markers are needed to identify these patients early.
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